Open an account

Translational Development Acquisition

TDAC · NASDAQ

$10.81+$0.00 (+0.00%)TodayMarket closed ·
Prev close $10.81

About TDAC

Translational Development Acquisition Corp. is a blank check company that was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company is headquartered in New York City, New York. The company went IPO on 2024-12-23. The firm is formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The firm has not selected any specific business combination target, and has not engaged in any substantive discussions, directly or indirectly, with any business combination target. The firm has neither engaged in any operations nor generated any revenues.

Employees
0
Headquarters
New York City, New York
Listed
Dec 23, 2024
Sector
N/A
Industry
N/A

TDAC key statistics

Market cap
208.73M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
7.80K
Volume
1.69K
Open price
$10.86
High today
$10.86
Low today
$10.81
52 Week high
$10.95
52 Week low
$10.41

Translational Development Acquisition (TDAC) at a glance

As of Oct 23, 2026, Translational Development Acquisition (TDAC) shares are priced at $10.81, giving the company a market cap of 208.73M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $10.81 and $10.86. The current price is 0.0% above the day's low and 0.5% below its high.

Volume so far is 1.69K shares, below the average of 7.80K shares a day.

Over the past year Translational Development Acquisition has ranged from $10.41 to $10.95, and now sits 74% of the way up that range.

TDAC news

  • Press releasePRNewswire

    $HAREHOLDER ALERT: The M&A Class Action Firm Announce the Investigation of the Merger - WEAV, BRBS, TDAC and UHG

  • Press releaseBusiness Wire

    Translational Development Investor Alert: Kahn Swick & Foti, LLC Investigates Translational Development Acquisition Corp. - TDAC

  • Press releasePRNewswire

    TDAC Announces ProLogium's Filing of F-4 As Continuing Momentum Towards Merger

  • Press releasePRNewswire

    TDAC Announces Very Successful Share Redemption Results in Connection with Extension Vote

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.